Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aptevo Therapeutics Inc. (APVO)
Price$1.85Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.1M | $12.3M | $4.3M | $32.4M | $23.1M | $14.7M | $10.0M | $33.6M |
| Gross profit | — | — | — | — | — | — | $12.5M | $11.9M | $9.6M | −$2.5M | $16.7M |
| Gross margin | — | — | — | — | — | — | 38.54% | 51.39% | 65.82% | −24.86% | 49.61% |
| Research & development | $14.5M | $14.4M | $17.1M | $17.9M | $19.0M | $17.9M | $24.8M | $35.4M | $29.0M | $29.1M | $34.7M |
| Operating expenses | $26.3M | $24.6M | $28.9M | $31.8M | — | — | $53.5M | $63.5M | $63.6M | $136.3M | $77.8M |
| Operating income | −$26.3M | −$24.6M | −$28.9M | −$28.6M | −$21.4M | −$27.5M | −$41.0M | −$51.7M | −$53.9M | −$138.8M | −$61.1M |
| Operating margin | — | — | — | −919.75% | −174.10% | −638.06% | −126.33% | −223.98% | −368.05% | −1,389.81% | −181.84% |
| EBITDA | −$26.1M | −$24.3M | −$28.3M | −$27.7M | −$20.3M | −$26.1M | −$38.7M | −$49.3M | −$50.8M | −$135.4M | −$58.2M |
| EBITDA margin | — | — | — | −890.82% | −164.79% | −605.43% | −119.44% | −213.62% | −346.72% | −1,356.14% | −173.19% |
| Net income | −$26.0M | −$24.1M | −$17.4M | $8.0M | −$28.5M | −$17.8M | −$40.4M | −$53.7M | $7.0M | −$112.4M | −$59.3M |
| Net profit margin | — | — | — | 257.77% | −231.51% | −411.93% | −124.75% | −232.75% | 47.57% | −1,125.84% | −176.53% |
| Basic EPSper basic share | -$87.27 | -$174,760,000.00 | -$5,713,763,145,861.91 | $6,317,329,675,354.37 | -$3,053,040,695,016,004,000.00 | -$2,630,544,124,371,285,000.00 | -$6,971,193,415,637,860,000.00 | -$237,034,460,995,511,300,000.00 | $32,728,607,585,154,277,000.00 | -$550,435,673,023,049,200,000.00 | -$290,590,364,316,672,820,000.00 |
| Diluted EPSper diluted share | -$87.27 | -$174,760,000.00 | -$5,713,763,145,861.91 | $6,317,329,675,354.37 | -$3,053,040,695,016,004,000.00 | -$2,630,544,124,371,285,000.00 | -$6,971,193,415,637,860,000.00 | -$237,034,460,995,511,300,000.00 | $32,728,607,585,154,277,000.00 | -$550,435,673,023,049,200,000.00 | -$290,590,364,316,672,820,000.00 |
Owners
Reported shareholders
≈6.94%of listed shares
NIOWAVE, INC.98.52K shares · May 25, 2026
View holders
| Holder | % owned |
|---|---|
NIOWAVE, INC. | ≈6.94%98.52K shares |
GSA CAPITAL PARTNERS LLP | 1.52%21.54K shares |
Grant Grady III | ≈0.95%13.51K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.90%12.71K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.76%10.82K shares |
VANGUARD FIDUCIARY TRUST CO | 0.29%4.14K shares |
UBS Group AG | 0.05%730 shares |
OSAIC HOLDINGS, INC. | 0.03%360 shares |
SBI Securities Co., Ltd. | <0.01%109 shares |
BARCLAYS PLC | <0.01%31 shares |
BOFA SECURITIES, INC. / BANK OF AMERICA NA / BANK OF AMERICA CORP /DE/ | ≈<0.01%27 shares |
White Marvin L | ≈<0.01%12 shares |
Lamothe Jeffrey G. | ≈<0.01%6 shares |
Kwon SoYoung | ≈<0.01%4 shares |
Taylor Daphne | ≈<0.01%3 shares |
DANSKE BANK A/S | <0.01%1 shares |
Harsanyi Zsolt | ≈<0.01%1 shares |
Abdun-Nabi Daniel | ≈<0.01%1 shares |
Niederhuber John | ≈<0.01%1 shares |
Kunz Barbara Lopez | ≈<0.01%1 shares |
Percentages use 1.42M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 10, 2025Form 4 | Grant Grady IIIDirector | BuyCommon Stock | 13.5K | $1.49 | $20.1K | 13.5K |